PRESS RELEASE

Published May 30, 2024

Today we announced the landmark overall survival results from our Phase 3 CARES-310 trial in first-line #uHCC. The results will be presented at an in-person poster presentation on June 1 at #ASCO2024. Read more here: Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma #ElevarAtASCO

Rare disease science addict, humble servant to unmet patient needs

4mo

Congrats

National Life Sciences Business Development Leader at RSM US LLP, Board of Advisors

5mo

Great news! Longest median overall survival for any treatment in a global Phase 3 trial in uHCC. Amazing.

Executive Assistant Professional -Time Management l Event Planning l Calendaring l Meeting Scheduling l Complex Global Travel

5mo

Congratulations Elevar! That is such fantastic news! Keep up the great work.

To view or add a comment, sign in

Insights from the community